Enifer is a technology company.
Enifer is a biotech start-up based in Espoo, Finland, founded in 2020. We harness the power of fungal fermentation to upcycle agrifood industry byproducts into nutritious mycoprotein ingredients.
Enifer has raised $17.0M across 2 funding rounds.
Enifer has raised $17.0M in total across 2 funding rounds.
Enifer has raised $17.0M in total across 2 funding rounds.
Enifer's investors include Nordic FoodTech VC, Voima Ventures.
Enifer is a Finnish biotech company specializing in sustainable protein production through fungal fermentation. It develops and commercializes PEKILO® mycoprotein, a fungi-based protein ingredient derived from circular economy by-products, serving the aquafeed, pet food, and food production industries. PEKILO® offers a nutritious, neutral-tasting, and environmentally friendly alternative to traditional animal and plant proteins, with a low water and land footprint. Enifer has demonstrated strong growth momentum, securing over $53 million in funding and partnerships with global industry leaders like Skretting, Purina, and Valio[1][2][3][4].
Founded in 2020 as a spin-off from the VTT Technical Research Centre of Finland, Enifer was established by five scientists who aimed to advance and commercialize the proprietary PEKILO® technology. This technology, originally developed and used by the Finnish forest industry since the 1970s, enables the biotechnological conversion of dilute industrial side streams into high-protein fungal biomass. Enifer has modernized and optimized this process using contemporary biotechnology to address global protein demand sustainably[1][2][6].
Enifer rides the global trend toward sustainable and alternative protein sources driven by environmental concerns, resource scarcity, and consumer demand for ethical food production. The timing is critical as the food industry seeks scalable, low-impact protein solutions to replace or supplement animal and plant proteins. Enifer’s circular economy approach aligns with increasing regulatory and market pressures to reduce waste and carbon emissions. By enabling the use of industrial by-products, Enifer contributes to a more sustainable food ecosystem and influences the broader adoption of biotechnology in food production[1][2][3][4].
Enifer is poised for significant growth with its new production facility in Kantvik, Finland, expected to produce 3,000 tons of mycoprotein annually starting in 2025. Future trends shaping its journey include rising demand for sustainable proteins, regulatory approvals such as Novel Food status, and expanding applications in various food sectors. As Enifer scales, its influence may extend beyond protein supply to shaping circular bioeconomy practices and fostering innovation in fungal biotechnology. The company’s legacy technology combined with modern biotech advances positions it well to feed a growing global population sustainably[4].
Enifer has raised $17.0M across 2 funding rounds. Most recently, it raised $16.0M Series B in May 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2024 | $16.0M Series B | Nordic FoodTech VC, Voima Ventures | |
| Oct 1, 2020 | $1.0M Seed | Nordic FoodTech VC, Voima Ventures |